Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.

@article{Abeloff1984PhaseIT,
  title={Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.},
  author={Martin D. Abeloff and Milan Slavik and Gordon D. Luk and Constance A. Griffin and Johann Hermann and Oscar Blanc and Albert Sjoerdsma and Stephen B. Baylin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1984},
  volume={2 2},
  pages={124-30}
}
alpha-Difluoromethylornithine (DFMO), an enzyme-activated, irreversible inhibitor of ornithine decarboxylase, blocks polyamine biosynthesis and has antitumor effects in animal tumor models as well as in athymic mice implanted with human small cell carcinoma. This study was designed to determine the maximally tolerated dose of oral DFMO administered every six hours for 28 days to patients with advanced solid tumors or lymphomas. DFMO levels were measured using an ion exchange chromatographic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.

The Journal of neuroscience : the official journal of the Society for Neuroscience • 2015
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…